EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Sanofi, which is joining a growing number of ... Opella employs 11,000 people globally and sells popular French pain medicine Doliprane, as well as brands including Mucosolvan cough syrup, Allegra ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Emanuele de Rinaldis, global head of precision medicine and computational biology at Sanofi, commented: “[O]ur drug discovery strategy is driven by precision medicine. We seek to describe ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

This agreement follows Sanofi’s announcement of an exclusive ... This novel precision medicine approach aims at changing the standard of care in some rare cancers to extend patients’ lives ...

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical ...

Sanofi, through its philanthropic organisation Foundation S, is celebrating the 25th anniversary of The Gaucher Initiative, a ...

This novel precision medicine approach aims at changing the standard of care in some rare cancers to extend patients’ lives and improve their quality of life. Paul Hudson CEO, Sanofi “We are ...